MARATTO

article · Benha Journal of Applied Sciences

Beta 1 Integrin in Hair Follicles of Patients with Androgenetic Alopecia

Abstract

Background: Androgenetic alopecia (AGA) is a hereditary hair loss illness characterized by a slow but steady transition from terminal to indeterminate and, eventually, vellus hairs. The process by which cells adhere to both the extracellular matrix and other cells is mediated by heterodimeric transmembrane proteins called integrins, which include of an α and a β component. The purpose of this paper is to examine the association between the severity of AGA etiopathogenesis and the tissue expression of β1 integrin, as well as to evaluate its participation in this process. Results: Beta 1 integrin has the potential to be an indicator of AGA severity and a key player in the disease's etiology. Background: Androgenetic alopecia (AGA) is a hereditary hair loss illness characterized by a slow but steady transition from terminal to indeterminate and, eventually, vellus hairs. The process by which cells adhere to both the extracellular matrix and other cells is mediated by heterodimeric transmembrane proteins called integrins, which include of an α and a β component. The purpose of this paper is to examine the association between the severity of AGA etiopathogenesis and the tissue expression of β1 integrin, as well as to evaluate its participation in this process. Results: Beta 1 integrin has the potential to be an indicator of AGA severity and a key player in the disease's etiology.

Research topics

  • Hair Growth and Disorders

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/bjas.2024.300703.1442

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.